Anticancer agent 57 exhibits potent inhibitory effects against MDA-MB-231, MDA-MB-468, and MCF-7 cells (IC50 = 6.43–8.00 μM); induces cell cycle arrest and significantly promotes apoptosis; inhibits tumor growth in MDA-MB-231 xenograft nude mice; and can be used for the study of triple-negative breast cancer (TNBC).